The p53-immunoreactivity was defined as positive when staining in > 10% of the tumour cells and it was found that p53-immunoreactivity was correlated with poor OS in patients with colorectal tumours with distant metastases, but not in the entire cohort of 124 GEP-NEC patients, nor in the pancreatic primaries. Here, TP53 is linked to neuroendocrine carcinoma.